Table 5.

Effects of supplementing Qi and Activating blood circulation on VEGF, Ang, bFGF content in APP/PS1 double transgenic ischemic mice (ng/mg, $\bar{x}±s$)

Group	n	VEGF	Ang	bFGF
C57 sham-operated	10	9.6±1.2	1.6±0.5	6.4±2.1
C57 ischemia	10	12.4±2.4a	1.5±0.2	6.6±0.5
APP/PS1 model	10	6.8±1.7a	1.2±0.8	5.8±2.4
APP/PS1 ischemia	10	10.5±3.0	1.4±0.5	5.6±1.6
C57BL ischaemic + aspirin	10	10.4±2.3	1.9±0.6	8.7±2.5
C57BL ischaemic + SLT	10	14.3±1.5b	2.9±0.7b	9.6±2.5b
APP/PS1 + SLT	10	13.6±4.1c	1.9±0.7	9.8±1.6
APP/PS1 ischaemic + donepezil hydrochloride	10	10.4±2.0c	2.0±0.3c	5.8±1.4
APP/PS1 ischaemic + SLT	10	13.7±1.3c	2.0±0.4c	7.0±1.9c

Notes: ischaemic treatment: both right and left common carotid arteries were separated, and the arterial blood vessel was stimulated with a temperature-controlled current of 80 mu A using an in vivo thrombometer to cause thrombosis. The APP/PS1 ischaemic + donepezil hydrochloride group were administered intragastrically with 20 mg·kg^-1·d^-1 of donepezil hydrochloride. The C57BL ischaemic + aspirin group were administered intragastrically with 32 mg·kg^-1·d^-1 of aspirin, the SLT group were administered intragastrically with 32 mg·kg^-1·d^-1 of SLT and the control group were given 32 mg·kg^-1·d^-1 of solvent. Duration: two months. SLT: Sailuotong; APP: amyloid precursor protein; PS1: presenilin-1; VEGF: vascular endothelial growth factor; Ang: angiopoietin; bFGF: basic fibroblast growth factor. One-way analysis of variance was employed to make comparisons among groups, and in the case of the normal distribution, Tukey’s post hoc test was conducted; otherwise, the Kruskal-Wallis test was adopted. Compared with C57 sham-operated group, ^aP < 0.05, compared with C57 ischemia group, ^bP < 0.05, compared with APP/PS1 ischemia group, ^cP < 0.05.